There is a significant amount of institutional holding here, definitely a good sign. That doesn't mean things are just peachy. TELK really needs to bring one or more of these drugs to market and get some sort of revenue stream going. There has been quite a bit of time and money poured into R&D here.
Having said that, this is one of the few stocks in this sector that I've really done a significant amount of DD on. The amount of time and money invested thus far may not be too far out of line with the sector. I'd be interested to hear your thoughts on that, or from anyone else who is more familiar with the sector. If it were me, I'd either be very confident or very concerned at this point.
The other 600 lb gorilla here is the possibility of delisting from NASDAQ. They were given until today to regain the minimum $1 bid. Delisting could mean losing institutional investors. If there is a mass exodus that results in a drop in price, I'll gladly jump back in (I currently am not holding this). As far as I'm concerned, NASDAQ or not, I like where TELK is headed. The TRAP platform seems like it has a lot of potential, as do the drugs that are in the pipeline.
News 
Market Data 
Discover 
